Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

Model scores of the 29,894 trials active now.

Model score 15% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (607 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-05-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: stagepriorno knownchemotherapyto registration
  Phrases that lowered it: patientsaminotransferasereceivesinglephase iii
• Phase: 3 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: 16.9% (lowers risk) · Drug's FDA history
• Sponsor's past termination rate: 7.0% (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Sponsor's past trials: 298 (lowers risk) · Sponsor's track record
• Primary purpose: supportive care (lowers risk) · Design
• Drug's FAERS reports before start: 274073 (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports in the prior 12 months: 54254 (lowers risk) · Drug's FDA history
• Blinding: double (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Drugs with FDA adverse-event history: 6 (lowers risk) · Drug's FDA history
• Responsible party: sponsor (lowers risk) · Design
• Drug's FAERS reports marked serious: 83.8% (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy NCT02116530 · started 2014 · scored riskier than 58% of active trials completed
• Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients NCT03137121 · started 2017 · scored riskier than 97% of active trials completed
• Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapy NCT04075955 · started 2019 · scored riskier than 44% of active trials completed
• Olanzapine and 5-HT3 With or Without Dexamethasone to Prevent CINV NCT05805800 · started 2023 · scored riskier than 44% of active trials completed
• Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients NCT03079219 · started 2017 · scored riskier than 54% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.